Last reviewed · How we verify
TAFASITAMAB
Tafasitamab is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its current market presence, leveraging its approved status to generate ongoing revenue. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics and biosimilars.
At a glance
| Generic name | TAFASITAMAB |
|---|---|
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
Common side effects
- Neutropenia
- Fatigue
- Anemia
- Diarrhea
- Thrombocytopenia
- Cough
- Pyrexia
- Peripheral edema
- Respiratory tract infection
- Decreased appetite
Serious adverse events
- Infections
- Pneumonia
- Febrile neutropenia
- Cerebrovascular accident
- Respiratory failure
- Progressive multifocal leukoencephalopathy
- Sudden death
Key clinical trials
- Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (PHASE2)
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL (PHASE2)
- Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (PHASE2)
- A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (PHASE2)
- Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (PHASE1, PHASE2)
- Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder (PHASE2)
- Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAFASITAMAB CI brief — competitive landscape report
- TAFASITAMAB updates RSS · CI watch RSS